HLN.L

Haleon plc
Haleon PLC - EMTN Programme: publication of supplement
9th September 2024, 08:15
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4150D
Haleon PLC
09 September 2024
 

 

 

EMTN programme: publication of supplement


9 September 2024: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the supplement (the "Supplement") to the base listing particulars (together with the Supplement, the "Base Listing Particulars") dated 3 May 2024 regarding Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s £10,000,000,000 Euro Medium Term Note Programme, guaranteed by the Company, has been published.

 

A copy of the Supplement, together with the Base Listing Particulars, is available for inspection at and can be downloaded from:

www.haleon.com/investors/debt-investors

 

Amanda Mellor

Company Secretary

 

Enquiries

Investors

Media

 

Sonya Ghobrial  

+44 7392 784784

Zoe Bird

+44 7736 746167

Rakesh Patel     

+44 7552 484646

Gemma Thomas

+44 7985 175048

 

Emma White

+44 7823 523562

 



Email: investor-relations@haleon.com 

Email: corporate.media@haleon.com 

 

 

About Haleon

 

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com.  

 

Disclaimer

 

Please note that the information contained in the Base Listing Particulars may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Listing Particulars) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Listing Particulars is not addressed.  Prior to relying on the information contained in the Base Listing Particulars, you must ascertain from the Base Listing Particulars whether or not you are part of the intended addressees of the information contained in the Base Listing Particulars.

 

Your right to access this service is conditional upon complying with the above requirement.

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PSPUKAWRSUUKRRR]]>
TwitterFacebookLinkedIn